If you or a loved one uses the Zecuity migraine patch, the makers of the patch and the FDA advise you to stop to avoid the risk of scars and burns.
Teva Pharmaceutical Industries recently announced it would temporarily suspend the sale, marketing, and distribution of Zecuity migraine patches following reports of scars and burns at the patch application site. Patients also reported suffering pain, severe redness, skin discoloration, blistering and cracked skin when using Zecuity.
Sumatriptan is the active ingredient in Zecuity, which delivers migraine pain relief medicine through a battery-powered patch worn around the upper arm or thigh, for a one-time use, for no more than 4 hours, and without exposure to water.
Teva recommends patients stop using the patch, and to speak with their healthcare provider about alternative migraine medication. Healthcare providers are instructed to stop prescribing Zecuity, and advise patients to stop using the patch to avoid the risk of burns and scars.
Teva will conduct safety studies to investigate the cause of the side effects, and has initiated a recall of the migraine patch from pharmacies. The FDA will evaluate the risk of scars and burns, and provide its findings in an updated safety bulletin for Zecuity patients.
In the continuing effort to keep defective drugs and medical devices off the market, please report any negative side effects suffered from using the Zecuity migraine patch to Teva at 1-800-996-5855, the FDA at 1-800-FDA-1088, or report side effects through the FDA’s MedWatch Safety Information and Adverse Event Reporting Program at http://www.fda.gov/MedWatch/report.